Certainly, HIV-protease inhibitors possess all the features useful to counter tumor vasculogenesis, since they down-regulate HIF-1, AKT, MAPK, eNOS, VEGF and MMP (Figure 1, Table 2). The gene discussed is AKT1; the disease is neoplasm.